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levels, determinants and intervention
strategies published between 2000 and
2017
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Oxana Mikhailovna Drapkina1, David Leon2,3 and Martin McKee2
Abstract
Background: Arterial hypertension (HT) is common in the Russian adult population, with half of affected individuals
inadequately controlled. Low adherence to medication seems likely to be a factor. We report a scoping review of
studies on adherence to antihypertensive therapy (AHT) in Russia to determine the extent of research undertaken,
the frequency of adherence among adults diagnosed with HT, methodologies used in the studies, and their ability
to describe determinants of adherence.
Methods: A scoping review of published studies that have assessed adherence to AHT in Russian HT patients
searched the main Russian and international electronic databases eLIBRARY.ru, Russian Medicine, Embase, MEDLINE
for full-text reports published in the Russian language between 2000 and 2017. The last search was on November
28, 2017. Among 520 reports identified, 31 were included in the review.
Results: Eighteen studies assessed adherence using the 4-item Morisky Medication Adherence Scale (MMAS-4);
others used bespoke questionnaires or pill counts. 25 studies assessed levels of adherence, 11 examined its
determinants, and 18 examined intervention strategies. The proportion of “adherent” patients varied from 11 to
44% using the MMAS-4, from 23 to 74% when using bespoke questionnaires, and from 5 to 43% when using pill
counts. Adherence was associated with sociodemographic factors, access to free drugs provided through the
Medicine Assistance Scheme (MAS), use of home blood pressure (BP) monitoring, anxiety, and comorbidity. There
was no evidence that adherence was associated with income or physical activity. Evidence of an association
between MAS, grade of HT, or experience of hypertensive crisis was inconclusive. Various methods to improve
adherence were studied including patient education (improved from 1.8 to 3.9 points, p = 0.0002 or 2.80 to 3.79
points, p < 0.0001 measured by the MMAS-4), telephone reminders (p < 0.0001), training in home BP monitoring
(p < 0.05), and use of fixed-dose combinations (p < 0.05).
(Continued on next page)
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Conclusions: The main determinants of adherence to AHT are sociodemographic characteristics, the severity of HT,
and presence of comorbidity. Patient education and use of fixed-dose combinations of drugs were identified as
most important for improving adherence. Most studies assessing adherence use self-reported methods so there is a
need for greater use of objective methods.
Trial registration: This scoping review has not been registered.
Keywords: Hypertension, Medication adherence, Scoping review
Background
Russia has one of the highest mortality rates from circula-
tory diseases in the world. In 2015 the age-standardized
death rate was 368.8 per 100.000 [1], 2.5–4 times higher
than in West European countries [1]. Arterial hyperten-
sion (HT) is among the main risk factors [2], affecting an
estimated 44% of the Russian adult population [3], with
only 53% of those with HT being controlled [3].
One reason for poor blood pressure (BP) control is
thought to be inadequate adherence to treatment, [4]
a substantial problem everywhere. A review of 21 clin-
ical studies conducted outside Russia found that ad-
herence to antihypertensive therapy (AHT) falls with
time from diagnosis, with about half of patients dis-
continuing treatment after one year [5]. This poor ad-
herence is, as expected, associated with treatment
failure and adverse cardiovascular events [6] while
good adherence has been linked to fewer adverse car-
diovascular outcomes [7].
The scale of the problem means that much research
has been undertaken to identify factors associated with
poor adherence and to develop measures to improve it.
However, while some of the conclusions from this work
are generalizable across countries, it is important to take
account of context, as there may be differences in health
beliefs (such as understanding of the importance of con-
tinuing treatment indefinitely for an asymptomatic con-
dition), health systems (such as how medicines are paid
for, and other circumstances). Moreover, context-spe-
cific evidence is more likely to be accepted by national
policy makers.
Here we report a scoping review of all Russian lan-
guage studies presented in full-text reports on the
problem of adherence to antihypertensive medication
in the Russian population, the factors associated with
adherence, interventions to improve adherence to treat-
ment, and their effectiveness. This makes two distinct
contributions. First, it provides the most detailed and
comprehensive overview of what is known from the
published literature about this important issue in
Russia, summarizing the often neglected corpus of work
published in the Russian language. Second, we have
summarized the results of research in the quantitative
indicators and described of the revealed patterns.
As many readers will be unfamiliar with the Russian
health system, we summarize the key elements of medi-
cines supplies in Table 1.
Research questions
We address the following questions by means of a scop-
ing review of the Russian language literature pertaining
to studies of adherence to antihypertensive medications
conducted in Russia:
1. What levels of adherence are found among adults
diagnosed as hypertensive?
2. What sociodemographic and clinical factors are
associated with adherence?
3. What robust evidence has been generated as to
effective interventions used in Russia to increase
adherence to treatment?
Table 1 Pharmaceuticals in the Russian health system
State medical institutions in the Russian Federation provide free medical
treatment to all in-patients but, after discharge, patients must pay the
full cost unless they are in one of the groups entitled to free
medications or at a 50% discount, as set out in a law from 1994. These
include children in large families who are under a certain age (3 or 6
depending on family size), those receiving the minimum pension,
invalids, veterans of the Great Patriotic War and other military
operations, and those involved in the Chernobyl disaster. Entitlement
extends to immediate family members. Since 2008, those in these
categories can choose an alternative, whereby they receive monetary
benefits instead. In practice, a growing number of the 19 million
potential beneficiaries choose monetary benefits, leaving less than 4
million receiving. This can be explained by how free and subsidized
medicines are available only in certain pharmacies in specific medical
institutions and a widespread belief that essential drugs are often
unavailable in these pharmacies. Those choosing monetary
compensation can thus obtain their medicines from private pharmacies,
albeit at additional cost. A recent study of medicines availability and
affordability in state and private pharmacies in six Russian citizens did,
however, find that common cardiovascular medicines were widely
available and, in private pharmacies, reasonably affordable. However,
where state pharmacies stocked generic versions, they did not also
stock branded equivalents [8].
Information on prescribing for hypertension in Russia can be found in
the RELIF III study. The most frequent classes of drugs were angiotensin-
converting-enzyme inhibitors (78%), diuretics (40%), beta-blockers (36%),
and calcium antagonists (19%). The authors reported that angiotensin-
converting-enzyme inhibitors were more likely to be taken regularly,
specifically Prestarium, Renitec, and Hartil [9].
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Methods
This scoping review was reported in accordance with
the reporting guidance provided in the Preferred
Reporting Items for Systematic reviews and Meta-Ana-
lyses statement extension for Scoping Reviews
(PRISMA-ScR) [10] (Additional file 1).
ScR protocol was not published.
Eligibility criteria
Reports were included in this scoping review if they met
the following criteria:
 Target population included the Russian adult
population aged 18 years and over with a diagnosis
of HT defined as BP ≥140/90 mmHg and/or taking
regular antihypertensive medication;
 Articles that report on adherence to AHT,
regardless of how adherence is measured;
 Types of study designs - randomized controlled trial
studies, non-randomized trial studies, observational
studies (cross-sectional, cohort studies), registers;
 Reports published in the Russian language;
 Full-text original reports;
 Published in journals or proceedings of conferences;
 Literature published from January 2000 to
November 2017. The last search was conducted in
November 28, 2017.
There was no restriction on duration of treatment or
sample size. There were no restrictions on interventions,
comparators, and outcomes.
Information sources
Searches of the main Russian and international electronic
databases were complemented by iterative searches using
Internet search engines, personal contact with Russian ex-
perts working on HT, and queries to authors of identified
studies by phone or e-mail (also used where clarification
was sought about survey methods, instruments (such as the
name of the questionnaire) and duration of observation).
Reference lists were also searched. This comprehensive ap-
proach was taken to reduce potential bias by including only
easy-to-locate studies that may have larger effect sizes due
to publication bias.
The Russian databases were:
– eLIBRARY.ru - the largest Russian information
portal (https://elibrary.ru/)
– Central Scientific Medical Library “Russian
Medicine” - second in size Russian medical
information portal (http://www.scsml.rssi.ru/)
The international databases were:
– Embase (https://www.elsevier.com/solutions/
embase-biomedical-research)
– MEDLINE (PubMed) (https://www.ncbi.nlm.nih.
gov/pubmed)
The search for sources was conducted between Octo-
ber 2017 and November 2017 (last date searched).
For eLIBRARY.ru 333 publications were obtained by
October 17, 2017.
For Russian Medicine 69 publications were obtained
by October 20, 2017.
For Embase 87 publications were obtained by Novem-
ber 10, 2017.
For MEDLINE (PubMed) 31 publications were ob-
tained by November 28, 2017.
The personal contacts with authors to identify add-
itional sources were conducted from December 2017 to
January 2018.
If more than one publication related to the same
study, all were used to provide as much information as
possible.
Full search strategies specific to the different databases
are provided in Additional file 2.
Study selection
Having eliminated duplicates, titles and abstracts were
reviewed by 2 researchers to assess eligibility, with differ-
ences resolved by discussion or, where necessary, by
consultation with a third team member. Those not avail-
able electronically were obtained as hard copies. Those
potentially eligible were read by each researcher to con-
firm eligibility and those retained were categorized to
covering one or both of the following two areas:
a) Levels, patterns and determinants of adherence
b) Interventions to improve adherence, including
evaluations of effectiveness
Each paper was read three times by a different team
member who extracted the key findings.
Data charting process
Authors created a matrix (an Excel spreadsheet) to
chart relevant information about all the sources
reviewed. Specifically, the chart included details about
the authors, year of publication, study setting, popula-
tion/participant selection criteria, study design, sample
size, age of participants, HT grade, nature of interven-
tion, adherence measure, factor associated with adher-
ence and main results (Table 2, Additional files 3, 4
and 5). Matrix was piloted with five papers and adapted
in the light of this experience.
Bochkareva et al. Archives of Public Health           (2019) 77:43 Page 3 of 16
Table 2 Characteristics of included studies on adherence to antihypertensive therapy in adult population in Russia from 2000 to
2017
Reference Year of
publication
Study setting Participant
selection criteria
Design Sample
size
Age (years) HT gradea Critical appraisal/
quality assessment
of findings
(a) Strengths
(b) Weaknesses
Ageev et al.
[11]
2008 Patients who
visited outpatient
department of
the Russian
Cardiology
Scientific and
Production
Center
Men or women
older than 18, with
SBP 140–179
mmHg, DBP 99–
100mmHg, high
cardiovascular risk,
not taking of ACE
inhibitors and
diuretics, without
secondary HT,
heart failure, renal
and hepatic
impairment,
insulin-treated DM.
Recruitment
process not
described
Randomized
non-blinded
controlled
intervention
study
60 62.5 ± 2.2 1–3 (a) prospective
study, follow up
period 6 mth;
(b) small sample
size,
incorrect DBP level
in inclusion criteria
Kobalava et
al. [12, 13]
2011 Patients
attending 240
cardiologists in 17
Regions
Men or women
with uncontrolled
HT, non-adherent,
absence of
contraindications
to ACE inhibitors
taking, no
eligibility to
receive MAS
Randomized
non-blinded
controlled
intervention
study
906 56.2 ± 10.6
(female)/
54.9 ± 10.9
(male)
Uncontrolled
HTb
(a) multicenter
study, follow up
period 12 mth, big
sample size;
(b) including only
non-adherent
patients
Sarycheva et
al. [14]
2017 Single outpatient
clinic in Moscow
Region.
300 patients have
been examined
before 150
patients included
Men or women
aged 40–65, with
ineffective
treatment of HT
and dyslipidemia,
SBP > 140mmHg,
DBP > 90mmHg,
without IHD, DM
and other severe
diseases
Randomized
non-blinded
controlled
intervention
study
150 40-65y HT patients
with high
cardiovascular
risk
(a) follow up
period 12 mth;
(b) there are no
basic data of
adherence
Fofanova et
al. [15]
2008 Patients who
visited outpatient
department of
the Russian
Cardiology
Scientific and
Production
Center
Men or women
older than 18, with
SBP 140–179
mmHg, DBP 99–
100mmHg, not
taking of ACE
inhibitors and
diuretics, without
secondary HT,
heart failure, renal
and hepatic
impairment,
insulin-treated DM.
Recruitment
process not
described
Randomized
non-blinded
controlled
intervention
study
60 61.2 ± 1.8
(female)/
61.8 ± 2.1
(male)
1–2 (a) patients with
high and very high
cardiovascular risk
are included, for
which adherence
to therapy is
particularly
important, follow
up period 6 mth;
(b) small sample
size, incorrect DBP
level in inclusion
criteria
Karpov et al.
[16]
2013 Patients
attending any of
700 cardiologists
in 51 Regions,
each recruiting 3
patients
Men or women
older than 18, with
uncontrolled HT
on treatment.
Recruitment
process not
described
Prospective
observational
intervention
study
2120 22–88 y 2–3 (a) big sample size,
multicenter study;
(b) relatively short
follow up period 3
mth and no
control group
Glezer et al. 2016 Patients Men or women Prospective 940 56.5 ± 11.5 1–2 (a) big sample size,
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Table 2 Characteristics of included studies on adherence to antihypertensive therapy in adult population in Russia from 2000 to
2017 (Continued)
Reference Year of
publication
Study setting Participant
selection criteria
Design Sample
size
Age (years) HT gradea Critical appraisal/
quality assessment
of findings
(a) Strengths
(b) Weaknesses
[17] attending 197
physicians in 48
Regions
aged 18–79, with
essential HT, SBP
≥140mmHg, DBP
≥90, but <110
mmHg
observational
intervention
study
multicenter study;
(b) relatively short
follow up period 3
mth, no control
group
Glezer et al.
[18]
2015 Patients
attending 243
physicians in 51
Regions
Men or women
older than 18, with
HT taking 2 or
more
antihypertensive
drugs who have
not reached their
BP target, SBP
140–179mmHg,
DBP 90–109
mmHg, without
contraindications
to ACE inhibitors
and calcium
channel blockers
Prospective
observational
intervention
study
1351
included,
1061
completed
the
protocol
59.4 ± 11.1 Essential HT (a) big sample size,
multicenter study;
(b) relatively short
follow up period 3
mth, no control
group
Glezer et al.
[19]
2016 Patients
attending 442
physicians in 29
cities
Men or women
older than 18, with
HT on treatment
who have not
reached their BP
target
Prospective
observational
intervention
study
1969 60.1 ± 0.3 No data (a) big sample size,
multicenter study;
(b) relatively short
follow up period 3
mth, no control
group
Kagramanyan
[20]
2015 Not stated
The author is
affiliation at
Yaroslavl State
Medical University
Men or women
aged 18–80, with
grades 1–3 of HT,
who visited the
Municipal Clinical
Hospital
Prospective
observational
intervention
study
50 64.06 ± 0.49
(female)/
61.88 ± 1.28
(male)
1–3 (a) studying of
adherence in
patients with 3
different socially
significant
nosologies - HT,
asthma and
alcohol abuse;
(b) small sample
size, large age
range, the real
number of HT
patients is
represented
incorrectly
Kaskaeva et
al. [21]
2015 Not stated Male patients
aged 20–64 with
grades 1–3 of HT.
Recruitment
process not
described
Non-
randomized
comparison
of 3 groups
250 20–64 y
(male)
1–3 (a) patients of
employable age +
relationship
adherence to job;
(b) described as
randomized but
groups selected on
basis of
employment: train
drivers (112), other
railway workers
(50), non-railway
workers (88)
Ushakova et
al. [22]
2005 Regional
cardiology clinic
in Ivanovo city
Men or women
with grade 2 of HT
on treatment,
without IHD and
DM
Prospective
observational
intervention
study
52 50.08 ± 7.25 2 (b) small sample
size, no control
group, patients
with grade 2 of HT
only included
Chazova et al. 2014 Patients who Recruitment Prospective 193 60.3 ± 8.0 No data (a) scope of
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Table 2 Characteristics of included studies on adherence to antihypertensive therapy in adult population in Russia from 2000 to
2017 (Continued)
Reference Year of
publication
Study setting Participant
selection criteria
Design Sample
size
Age (years) HT gradea Critical appraisal/
quality assessment
of findings
(a) Strengths
(b) Weaknesses
[23] visited outpatient
department of
the Russian
Cardiology
Scientific and
Production
Center
process not
described
observational
intervention
study
sessions with
patients, duration
of sessions and
number of the
studying patients
in group
corresponded to
the standards
approved by the
Ministry of Health,
it is important for
working at
outpatient care
settings;
(b) the control
group is formed
from abandoning
the patient
education, the
number of patients
in the control
group is 2 times
less than in the
intervention group
(65:128), short
follow up period 6
weeks
Fofanova et
al. [24]
2009 Patients
attending 185
cardiologists in 84
policlinics of
Moscow
Men or women
with SBP 140–179
or DBP 99–100
mmHg, not taking
calcium channel
blockers
Cross-
sectional
4816 62.2 ± 0.2 1–2 (a) big sample size;
(b) incorrect DBP
level in inclusion
criteria, only
possible to extract
baseline data
Donirova et
al. [25]
2012 Ambulatory care
facility
Men or women
with HT on
treatment
Cross-
sectional
74 18 y and
older
No data (b) small sample
size (14 vs 60)
Loukianov et
al. [26]
2017 Patients
attending 185
physicians or
cardiologists of
the same from 3
randomly
selected
outpatient clinics
of Ryazan and the
Ryazan region in
March–May 2012
(consecutive
inclusion of all
who applied from
March 01 to May
27)
Patients older than
18, with
combination of
IHD, HT, chronic
heart failure,
permanent
residence in the
Ryazan and the
Ryazan region
Register 2303 70.3 ± 10.7
(ppl with
history of
MI),
69.9 ± 11.0
(ppl without
history of
MI)
1–3 (a) collection of
adherence data
using MMAS-4 in a
large outpatient
register
(b) all patients,
irrespective of
history of MI, had
complex pathology
of IHD, HT and
chronic heart
failure. Therefore it
is impossible to
estimate
independent
association
between HT and
adherence.
Fofanova et
al. [27]
2014 Patients who
visited outpatient
department of
the Russian
Cardiology
Scientific and
Production
Men and women
with HT and
examined by
psychiatrists
Cross-
sectional
161 19–75
(female)/
53.4 ± 11.4
(male)
1 (a) assessment of
adherence and
psychosomatic
aspects;
(b) groups selected
on basis of
adherence to
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Table 2 Characteristics of included studies on adherence to antihypertensive therapy in adult population in Russia from 2000 to
2017 (Continued)
Reference Year of
publication
Study setting Participant
selection criteria
Design Sample
size
Age (years) HT gradea Critical appraisal/
quality assessment
of findings
(a) Strengths
(b) Weaknesses
Center treatment: low adh
– 131 ppl, high
adh – 30 ppl
Soboleva et
al. [28]
2012 Regional clinical
hospital and
ambulatory care
facility
Patients with
grades 1–3 of HT
and cardiovascular
disease.
Recruitment
process not
described.
Cross-
sectional
242 18 y and
older
1–3 (b) only possible to
extract baseline
data
Oganov et al.
[29]
2007 Patients
attending 512
physicians in 20
cities
Men or women
with HT and/or
IHD
Cross-
sectional
2496 18 y and
older
1–3 (a) big sample size;
(b) no prospective
stage
Olejnikov et
al. [30]
2014 Not stated
The authors are
affiliation at
Penza State
Medical University
Men or women
older than 60, with
grades 1–2 of HT.
Recruitment
process not
described
Cross-
sectional
75 66.6 ± 4.7 1–2 (a) studying
adherence in the
elderly;
(b) non-standard
way of MMAS-4
analyze, small
sample size, only
possible to extract
baseline data
Smirnova et
al. [31]
2012 Ambulatory care
facility
Patients aged 45–
75, with grades 1–
2 of HT.
Recruitment
process not
described
Randomized
non-blinded
controlled
intervention
study
60 Intervention
group: 62 ±
9.4, control
group: 63 ±
8.9
1–2 (a) complex
intervention on
adherence;
(b) small sample
size, relatively short
follow up period –
3 mth
Vologdina et
al. [32]
2009 Not stated Men and women
with IHD and
grades 1–2 of HT.
Recruitment
process not
described
Randomized
non-blinded
controlled by
closed
envelope
method
70 80.7 ± 2.7
(female)/
80.3 ± 2.5
(male)
1–2 (a) studying
adherence in the
elderly;
(b) small sample
size, relatively short
follow up period –
3 mth
Sviryaev et al.
[33]
2006 Ambulatory care
facility
Men or women
older than 18, with
grades 1–2 of HT
with irregular
therapy
Prospective
observational
intervention
study
115 51.3 ± 9.6 1–2 (a) follow up
period 6 mth;
(b) no control
group, numerical
indicators of
adherence level
aren’t presented in
the publication
Morozov et al.
[34]
2010 The authors are
affiliation at
Russian military
medical
Academy, St.
Petersburg
Patients with
grades 1–2 of HT
Cross-
sectional
86 30–73 y
(54 ± 4,8)
1–2 (b) only possible to
extract baseline
data, non-standard
way of MMAS-4
analyze
Kotovskaya et
al. [35]
2015 Patients
attending 830
physicians in 113
cities
Men or women
older than 18, with
uncontrolled HT
taking ACE
inhibitors or
angiotensin
receptor blockers
Prospective
observational
intervention
study
2435 59.3 ± 11.2 Uncontrolled
HTb
(a) big sample size,
multicenter;
(b) MMAS modified
with 2 additional
questions, no
control group,
relatively short
follow up period –
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Data items
A range of variables were extracted from reports of
the studies.
Article details such as title, first author, date of
publication, year of distribution, publication status, re-
gion(s) in which the study was conducted, and insti-
tutional setting.
Study design: randomized or non-randomized trial, co-
hort study, case-control study, register-based. If the design
was a trial, we collected additional information on alloca-
tion concealment. Study objective, study duration, and
sample sizes were also extracted.
Definitions of adherence: type of adherence measure:
4-item Morisky Medication Adherence Scale (MMAS-4),
pill counts, bespoke questionnaire, etc.; indicators of ad-
herence: MMAS-4 score points, percentage achieving a
score of 4, pill counts compliance, and percentage of ad-
herent people etc. (Additional file 3).
Determinants of adherence were extracted. These in-
cluded baseline sociodemographic characteristics of HT
patients: sex, age, education level, marital status, employ-
ment status, income, living in a city; disability; clinical
characteristics of patients: HT grade, duration of HT,
physical activity; associated clinical conditions (for ex-
ample, ischemic heart disease, history of myocardial in-
farction, hypertensive crisis, etc.); concomitant diseases
(for example, diabetes mellitus, panic attacks, subclinical
depression, etc.); other data on instruments used in
Table 2 Characteristics of included studies on adherence to antihypertensive therapy in adult population in Russia from 2000 to
2017 (Continued)
Reference Year of
publication
Study setting Participant
selection criteria
Design Sample
size
Age (years) HT gradea Critical appraisal/
quality assessment
of findings
(a) Strengths
(b) Weaknesses
3 mth
Panov et al.
[36]
2015 Federal Medical
Research Center,
St. Petersburg
Patients with
grades 1–2 of HT
and IHD
Prospective
observational
intervention
study
60 57.65 ± 1.59 1–2 (a) follow up
period - 12 mth;
(b) small sample
size
Oschepkova
et al. [37]
2004 Patients who
visited outpatient
department of
the Russian
Cardiology
Scientific and
Production
Center
Men and women
aged 30–71, with
grades 1–2 of HT,
without MI, stroke,
heart failure, heart
arrhythmias.
Recruitment
process not
described
Randomized
non-blinded
controlled
intervention
study
30 54 ± 11 1–2 (a) home BP
devices as a way to
increase
adherence;
(b) described as
randomized but
main group – 19
ppl, control group
− 11, small sample
size
Kontsevaya et
al. [38, 39]
2015 Patients who
visited Outpatient
Cardiology Clinic
Men or women
with grades 1–3 of
HT
Cross-
sectional
1419 61.94 ± 0.26 1–3 (a) big sample size,
a large number of
factors associated
with adherence:
sociodemographic,
clinical, etc.;
(b) no prospective
stage
Kopnina et al.
[40]
2008 Not stated Patients with HT.
Recruitment
process not
described
Cross-
sectional
30 51 ± 1.14
(female)
2 (b) small sample
size, only women
are included in the
study
Sergeeva et
al. [41]
2012 Patients of the
cardiological and
endocrinological
department of
the Regional
Clinical Hospital
Men and women
with HT or HT +
DM.
Recruitment
process not
described
Cross-
sectional
190 With HT:
47.6 ± 0.4,
with HT +
DM:
44.7 ± 0.2
1–3 (a) association of
adherence with
hypertensive crisis
was shown;
(b) no data on
validation of
bespoke
questionnaire
ACE inhibitors, angiotensin converting enzyme inhibitors, CVD cardiovascular diseases, DBP diastolic blood pressure, DM diabetes mellitus, HT arterial hypertension,
IHD ischemic heart disease, MAS Medicine Assistance Scheme, MI myocardial infarction, MMAS-4 4-item Morisky Medication Adherence Scale, mth months, ppl
people, SBP systolic blood pressure
a Definitions of office blood pressure levels (mmHg): grade 1 hypertension: 140–159 and/or 90–99; grade 2 hypertension: 160–179 and/or 100–109; grade 3
hypertension: ≥180 and/or ≥ 110
b Uncontrolled HT was defined with patients not taking a previously prescribed therapy, registered in the medical records or insufficiently effective therapy
Bochkareva et al. Archives of Public Health           (2019) 77:43 Page 8 of 16
surveys; pharmacological therapy: therapeutic category,
INN and commercial name, drug administration schedule,
dose, dosage form; eligibility for the Medicine Assistance
Scheme (MAS) which provides free drugs for certain cat-
egories of patients; home BP device availability; and fre-
quency visits to the doctor (Additional file 4).
Intervention characteristics
Examples of content extracted included specific strategies
to address barriers to adherence: special packaging of
medications (e.g. blister packs, pill boxes), amount of pre-
scribed medications, eligibility for the MAS, interventions
designed to improve communication with patients, includ-
ing more frequent visits, motivational interviewing, patient
education, home BP monitoring, and provision of written
instructions etc. (Additional file 5); mode of delivery: face-
to-face, telephone, internet etc.; professions involved:
pharmacist, physician, etc.; duration and number of ses-
sions/consultations; and any other types of interventions
in the experimental group;
Other data recorded included the main results, BP dy-
namics, achievement of target BP levels, author’s conclu-
sions, and any reason for excluding the article.
Study quality assessment
In assessing the quality of study, we considered use of
validated questionnaires, objective methods for adher-
ence assessing, study design, presence of randomization,
blinding, sample size, and follow-up as appropriate.
Synthesis of results
We grouped the studies by study questions analyzed (ad-
herence, determinants and interventions), and summa-
rized the type of settings, populations and study designs
for each question, along with the measures used and a
summary of findings. The results of this scoping review
were synthesized using both a numerical summary, outlin-
ing relevant data from the included studies, and a narra-
tive synthesis interpreting the results.
Results
The initial search identified 520 references (Fig. 1). Of
these 120 were excluded because it was not possible to
obtain the abstract despite exhaustive searches. Most of
these were published in regional journals unavailable in
electronic format, with only tables of contents available
online, printed in individual regions in small numbers.
The remaining 400 were screened against the inclu-
sion criteria. The 235 potentially relevant reports were
reviewed as full texts (eight were not available electron-
ically, but three could be obtained as hard copies, leav-
ing 5, from local journals that could not be obtained),
leaving 31 eligible reports included in the review. The
results from 2 studies were presented in 2 separate
publications, resulting in us considering data from 29
individual studies.
The characteristics of the studies are presented in Table
2. Overall we included seven randomized intervention
studies, ten cross-sectional studies, eleven prospective ob-
servational intervention studies (including six multicenter
studies), and one report based on data from a register.
None of the randomized studies were blinded. In four of
the prospective observational intervention studies, it was
only possible to extract baseline data as follow up data
were not reported [24, 28, 30, 34]. Results from these
studies were transformed into cross-sectional data.
The total number of patients in the studies selected
for analysis was 23,127, with individual studies size ran-
ging from 30 to 4816 participants.
The duration of follow-up varied from 6 weeks to 48
months.
Adherence measurement
Adherence to AHT was assessed using MMAS-4 in 18
of the 29 studies. Ten studies used a bespoke question-
naire or a single question about regularity of taking
drugs that was included in a questionnaire on a wider
range of issues, supplemented with 3 clarifying ques-
tions. The bespoke instruments included pill counts in 6
studies; the MMAS-4 but analyzed in a non-standard
way in 1 study [34], and the Morisky-Green question-
naire, modified with 2 additional questions in one study
[35]. Several studies used more than one method, for ex-
ample MMAS-4 and pill counts.
No studies used objective methods of assessing adher-
ence - measurement of drugs in biological fluids in
blood, urine, or indirect methods - electronic dispensers.
The bespoke questionnaires were only available in Rus-
sian and there was no information about whether they
had been validated.
Adherence was assessed using data from cross-sec-
tional surveys and from baseline data in prospective ob-
servational intervention studies. In studies using the
MMAS-4 [11–19, 21, 23–27, 30, 33] adherence to AHT
varied from 1.62 ± 0.27 [11] to 3.12 ± 0.86 points [35]
out of a maximum of four (Additional file 3). Among
these studies, the highest rates of adherence were found
in post-marketing studies, all with large sample sizes.
Scores were 2.8 [19], 2.78 [16], 2.95 [18] and 3.12 ± 0.86
points [35]. In the studies reporting baseline adherence,
the highest rates were in those that included a high pro-
portion of patients with concomitant diseases: ischemic
heart disease, chronic kidney disease, stroke, transient is-
chemic attack, diabetes mellitus, etc. [29], who can be
expected to have a strong motivation to adhere to medi-
cation. The lowest baseline adherence rates, with scores
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of 1.62 [11] and 1.7 [31] were observed in studies with a
small number of patients who only had HT.
Eleven studies measured the proportion of “adherent”
patients, i.e. reporting 4 points on the MMAS-4. Results
varied, from 11.1% [15] to 44.2% [35]. The highest pro-
portion of “adherent” patients was again noted in a study
where many subjects had concomitant diseases [35].
Adherence, as measured by bespoke questionnaires
was reported in eight out of nine papers [20, 22, 28, 29,
37–41], one of the studies being published in two papers
[38, 39], three studies reporting baseline adherence [20,
22, 37]. In two studies, 38.5 and 74.9% of patients took
AHT daily [22, 38], in another 56% fully complied with
medical recommendations, including the use of antihy-
pertensive drugs [28], “high adherent”, “sufficiently ad-
herent” or “regularly taken” according to the criteria set
by the researchers varied from 23.3 to 60.5% [20, 29, 37,
40, 41]. However, these findings are difficult to compare
with those from other studies because of lack of infor-
mation on the instruments used.
Adherence using pill counts was examined in five
studies [31–34, 36] but baseline adherence rates were
reported in only 3, ranging from 5 [31] to 43% [32].
This large difference may reflect the small sample
sized (60 and 115).
Factors associated with adherence to antihypertensive
therapy
12 studies examined associations between adherence
and various socio-demographic, clinical and other vari-
ables (access to the MAS, home BP monitoring, fre-
quency of visits to a doctor, etc.). Higher adherence was
associated with female gender [29, 33, 35, 38, 41], age
over 50 years [29, 33], not living alone [29, 38], employ-
ment [27, 33], higher education [33], and living in a city
[41] (Additional file 4).
Fig. 1 Flow diagram indicating the study selection process on adherence to antihypertensive therapy in adult population in Russia from 2000
to 2017
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Higher adherence was associated with comorbidity, in-
cluding: ischemic heart disease [24, 29, 38], history of
myocardial infarction [26, 29], arrhythmias [27], diabetes
mellitus [24, 29, 35], and psychiatric disorders [27]. High
adherence was also associated with onset of HT at a young
age [27] and use of fixed dose combination therapy [38].
The findings of studies of the association between adher-
ence and grade of HT, experience of hypertensive crisis,
and duration of HT were not consistent [27, 29, 33, 38–41].
There was no evidence that adherence was associated
with income and physical activity [29].
Features of patient management in outpatient settings and
adherence to therapy
Home BP monitoring [24, 29, 31] and more frequent
visits to the doctor [34] were associated with better ad-
herence. The association with eligibility for the MAS
was also conflicting. In two studies [24, 39] it was associ-
ated with lower adherence [24] or failure to follow the
recommended regimen [39] but in another, there was no
association [38].
Taking multiple antihypertensive drugs (2 or more)
was associated with decreased adherence [35, 39].
Assessment the effectiveness of interventions aimed at
increasing adherence
Interventions to increase adherence were mainly either
patient education (in various forms) in 6 studies [12, 13,
19–23] or optimization of the drug administration regi-
men in 11 studies [11–13, 15–19, 32, 33, 35, 36], among
which 9 used a fixed-dose combination of drugs [11, 15,
16, 18, 19, 32, 33, 35, 36]. One study gave patients an
electronic version of the SCORE scale, with the phys-
ician showing the patient how their risk would be re-
duced if they stopped smoking, controlled their BP and
reduced their cholesterol [14]. In two studies [31, 37] pa-
tients were trained in home BP monitoring, intended to
increase adherence.
Several studies used more than one method to in-
crease adherence.
Randomized controlled intervention studies
In one study [12], a multi-faceted intervention, which in-
cluded information within an educational program for
patients, a free first package of antihypertensive drugs,
regular visits to the doctor, and telephone reminders,
was associated with a significant improvement in adher-
ence. After 12 months, the proportion of adherent pa-
tients who achieved an MMAS-4 of 4 points in the
intervention group was 71.7%, up from 52.2%, in the
control group. The difference at follow up was highly
significant (p < 0.0001) (Additional file 5). Demonstra-
tion of an electronic version of the SCORE scale to pa-
tients, highlighting benefits of reducing cardiovascular
risk by smoking cessation, BP control, and reduced chol-
esterol, was associated with higher adherence than in a
control group, with scores at 6 months of 2.75 and 1.88
points (p < 0.001), respectively, and 2.14 and 1.27 points
(p < 0.001), respectively after 12 months [14].
Training patients in home BP monitoring was associ-
ated with significant improvement in adherence, with
the effect persisting at 1 year [37].
Provision of an automatic BP monitor was associated
with a significant increase in adherence to AHT, with a
MMAS-4 score increasing from 1.7 ± 1.2 to 3.0 ± 1.1
points, p < 0.000 in the intervention group and from 5 to
96.4% (p < 0.001) in the index of compliance [31].
The use of fixed-dose combinations was associated
with better adherence to therapy in several studies
[11, 15, 16, 18, 19, 32, 33, 35, 36], including 3 ran-
domized non-blinded controlled trials [11, 15, 32].
Two of these used the MMAS-4 [11, 15] and the
other a compliance index [32].
Non-randomized intervention studies
Five studies evaluated so-called “patient education” or
similar interventions [19–23]. Those using the MMAS-4
reported increases from 2.80 to 3.79 points (p < 0.0001)
[19] or from 1.8 to 3.9 points (p = 0.0002) [23], while the
proportion of patients with an MMAS-4 of 4 points in-
creased from 38.6 to 57.9% (p = 0.04) [21]. Adherence, as
measured by a bespoke questionnaire improved from 27
to 67% (p < 0.05) [20]. The proportion of patients who
reported measuring their BP daily increased from 28.8 to
65.4% (p < 0.05) and taking antihypertensive drugs daily
increased from 38.5 to 82.7% (p < 0.05) [22].
The use of fixed-dose combinations of antihyperten-
sive drugs was evaluated in 7 non-randomized studies
[16–19, 33, 35, 36]. As in the randomized trial studies,
fixed-dose combinations were associated with significant
increases in adherence, as measured by the MMAS-4
compared to baseline [16–19, 33, 35].
Using bespoke questionnaires, consistently high adher-
ence was observed during the first year of treatment
with a fixed-dose combination of an angiotensin con-
verting enzyme inhibitor and calcium channel blocker,
at 97 and 93% at 6 and 12months respectively [36].
Critical appraisal/study quality assessment
Problems included the small number of randomized
studies none of which were blinded, heterogeneity of pa-
tient groups in non-randomized studies, small sample
size in some studies, heterogeneity of samples, presence
of concomitant pathology, use of subjective methods of
assessing adherence (questionnaires), and incomplete
presentation or selective reporting of results [42].
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Discussion
This is the first scoping review of Russian language studies
on adherence to AHT. Our search strategy was designed to
include as many primary publications as possible, although
it was concerning that abstracts for a large number of stud-
ies could not be located. This highlights an issue that has
not, to our knowledge, received adequate attention so far.
There are a large number of regional medical journals,
printed in small numbers, and while their tables of contents
are available electronically, their content (including ab-
stracts) is not. There is no central repository. While, in the-
ory, it might be possible to obtain copies from publishers,
the logistical barriers would be formidable and, given the
methodological weaknesses reporting in many of the papers
obtained, unlikely to be commensurate with the informa-
tion that might be extracted from them.
In accordance with the questions and objectives in
this scoping review, the key findings are as follows. Ad-
herence was assessed using MMAS-4 in 18 studies and
in other studies using bespoke questionnaires. In the
Russian population, the baseline MMAS-4 scores varied
from 1.62 ± 0.27 points [11] to 3.12 ± 0.86 points [35].
The proportion of patients with 4 points on the
MMAS-4 varied from 11.1% [15] to 44.2% [35], while in
studies using a bespoke questionnaire, the frequency of
adherence varied from 23.3% [40] to 74.9% [38]. The
latter were patients attending an outpatient cardiology
clinic. Relatively low levels of adherence were observed
in most studies [11, 20, 22, 23, 31, 32, 37, 40, 41]. These
findings are consistent with a cross-sectional study by
Cybulsky et al. on 1068 working-age men in Izhevsk,
Russia, which reported 41% of patients taking antihy-
pertensive drugs daily [43].
Many studies included quite large samples, from several
hundred to several thousand people [12, 13, 16–19, 24, 26,
29, 35, 38, 39], but some were much smaller, from 30 to 75
people [11, 15, 20, 22, 25, 30–32, 36, 37, 40]. The follow up
period varied from 6weeks [23] to 12months [12, 13, 36,
37]. One study lasted 4 years [16], but follow up data were
unavailable for analysis.
Studies of determinants of adherence identified being
female [29, 33, 35, 38, 41], age over 50 years [29, 33],
not living alone [29, 38], employment [27, 33], higher
education [33], and living in a city [41], comorbidity in-
cluding: ischemic heart disease [24, 29, 38], history of
myocardial infarction [26, 29], arrhythmias [27], and
diabetes mellitus [24, 29, 35]. These are consistent with
previous systematic review of studies from elsewhere
[44]. Data of association with anxiety level, panic at-
tacks and subclinical depression [19] differ from those
in the publication [44].
Evidence for an association between eligibility for the
MAS, grade of HT, and experience of hypertensive crisis
was inconclusive [24, 27, 29, 33, 38–41]. In two [29, 40],
patients with a higher BP were more adherent and in an-
other two [27, 33] better adherence was observed in pa-
tients with a lower grade of HT. In one [41], patients
who had experienced a hypertensive crisis had higher
adherence but in another [39] adherence was lower.
There were also conflicting findings on associations with
duration of HT. In three [29, 38, 40] patients with a long
history of HT were more adherent but the reverse was
observed two [27, 39]. One reason for such discrepancies
could be heterogeneity of patients included. In addition,
sample sizes varied greatly, with 1419 [38, 39], n = 161
[27], n = 190 [41] and n = 30 [40]. There was no evidence
that adherence was associated with income and physical
activity [29].
Almost all interventions studies found significant re-
sults, possibly reflecting publication bias. They included
optimization of the drug regimen [11, 15, 16, 18, 19, 32,
33, 35, 36], an educational program [12, 13, 19–23],
provision of an automatic home BP monitor [31, 37], and
an initiative to inform the patient of his or her risk [14].
Provision of an automatic BP monitor [31] and
optimization of the drug regimen using fixed combina-
tions [11, 15, 16, 18, 19, 32, 33, 35, 36] found to be ef-
fective elsewhere [45, 46], were associated with a
significant increase in adherence to AHT. However, in
several of the studies adherence also improved in con-
trol groups, most likely because both groups received a
series of enhancements to treatment including self-
monitoring diaries, and written recommendations on
lifestyle changes, as well as intensive monitoring of
both groups for the entire period of follow-up. Thus,
two of the randomized controlled studies found no dif-
ferences between intervention and control groups, in
adherence or BP reduction [31, 32]. The authors of two
studies [11, 15] concluded that the results support
fixed-dose combinations, but this seemed difficult to
justify from their findings.
Strengths and limitations
The randomized trials included, none of which were
blinded, had a high risk of systemic error (bias), while
using questionnaires that subjectively measure adher-
ence and reporting disparate numbers of patients in the
intervention and control groups [37], including only
non-adherent patients [12, 13], and in two randomized
non-blinded controlled trials no baseline adherence rates
were reported (incomplete data presentation) [14, 37].
As a consequence, the risk of a systemic error in our re-
view is close to critical.
In the vast majority of studies, the antihypertensive ef-
fect of adherence was measured as mean BP or probability
of achieving target BP levels. Only one study measured
24-h BP [30] or used home BP monitoring [37].
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Most studies used subjective methods of assessment,
namely questionnaires, including some developed by the
authors themselves, with no information on their testing
or validation. The only objective method used for asses-
sing adherence was indirect, using pill counts.
This situation is regrettable, because other methods
for assessing adherence exist, differing in the degree of
objectivity and information provided. The subjective
methods include, first, various validated questionnaires,
among which the MMAS-4 is most often used [47]. Sub-
jective methods of assessing adherence, based on a pa-
tient’s self-assessment, should be used with caution.
Adherence rates are overestimated by up to 20% com-
pared with an objective assessment [47]. Objective indir-
ect methods of assessing adherence include pill counts,
as well as various electronic dispensers [48]. Electronic
prescription and claims data on medication dispensed
has also been used to evaluate an adherence, assessed by
the proportion of days covered, although obviously it as-
sumes that medicines dispensed are actually taken [49,
50]. Abroad, a way of controlling adherence is available,
such as the analysis of electronic databases of pharmacy
chains [51]. The “gold standard” for assessing adherence
is measurement of drugs in biological fluids, for ex-
ample, in blood or urine, with the latter preferred as it is
less invasive [52].
Our findings suggest that interest in this issue is in-
creasing among Russian researchers. There were 85%
more publications in the period 2013 to 2017 than in
the previous five-year period. However, the methodo-
logical quality of the papers has not improved. There is
no obvious improvement in study design, with no more
randomized trials and although the MMAS-4 question-
naire has been used more often, the recent increase in
studies cannot be considered a major achievement.
Notwithstanding the many methodological weaknesses,
these findings suggest a picture of unsatisfactory adher-
ence to drug treatment in the Russian hypertensive popu-
lation. However, the quality of studies of adherence to
AHT is a serious problem not only in Russia, but also
internationally. The 2014 Cochrane review of interven-
tions to improve adherence [53] found only 13 studies on
AHT that were suitable for inclusion. It noted the unsatis-
factory (poor) overall level (quality) of such studies and
emphasized the need to use objective indicators of adher-
ence. For this purpose, Ascertaining Barriers for Compli-
ance project was developed [54], as well as Emerge’s
recommendations, that was published in order to solve
the lack of standard methods to assess adherence [55].
There were the limitations of the scoping review
process, e.g. last search dated was 2017, and reports
published only in the Russian language.
Despite the limitations of most of the studies included
this review makes a contribution in the following respects.
First, it is the first attempt to scope a comprehensive
picture of the Russian literature on this topic. An im-
portant contribution of this paper is that it captures the
full spectrum of research on adherence in Russia. It has
identified some large studies, with prolonged follow up,
using internationally accepted measures. Collectively, the
small number of better quality studies does offer insights
that can help inform the design of relevant policies, al-
though further evidence is essential. Adherence to AHT
in Russia is clearly a problem. Given the considerable
economic burden that this creates, borne by both pa-
tients themselves and the health system as a whole, this
is an issue that should be considered a high priority.
Second, the evaluative studies do point to some poten-
tially promising measures. However, all should be sub-
ject to further evaluation and there is a clear need for
much more research on interventions that have been
found to be promising elsewhere [56–58].
Conclusions
The main determinants of adherence to AHT are socio-
demographic factors, such as female gender, age over 50
years, not living alone, employment, higher education,
and living in a city; comorbidity, including: ischemic
heart disease, history of myocardial infarction, arrhyth-
mias, diabetes mellitus, and psychiatric disorders; adher-
ence was also associated with onset of HT at a young
age and use of fixed dose combination therapy. The
findings of studies of the association between adherence
and grade of HT, experience of hypertensive crisis, and
duration of HT were not consistent. Patient education,
telephone reminders, home BP monitoring and fixed-
dose combinations of drugs are most important for im-
proving adherence. The interpretations of these findings
are limited by unreliable measures of adherence. It is ne-
cessary to introduce objective methods for assessing of
adherence. A central repository of studies published in
regional medical journals should be created.
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